Thalidomide

THALOMID

Open Thalidomide in the interactive console ↗

Pronunciation: tha-LI-doe-mide

Thalidomide ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Thalidomide ballicule

What it isThe original immunomodulatory drug (IMiD), used for multiple myeloma and erythema nodosum leprosum.

Why this oneIts resurrection is the story: the teratogen that caused the limb-defect catastrophe proved to work in myeloma and leprosy reactions, founding the class that led to lenalidomide.

What limits itIt demands a locked-down pregnancy-prevention REMS, causes cumulative peripheral neuropathy and sedation, and adds venous thromboembolism risk requiring prophylaxis.

Thalidomide molecular structure (skeletal formula) — Molecular structure: Thalidomide

Thalidomide prescription history

Animated chart of estimated U.S. prescriptions per year, Oral anticancer meds (1953–2026). Thalidomide enters in 1998 (estimated).

Classes and tags

Clinical profile

Therapeutic safety burden4 / 4

Overdose danger1 / 4

Weight-gain liability1 / 4

Sedation liability3 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk4 / 4

Legacy pregnancy categoryX

Defining liabilityExtreme human teratogenicity and potentially irreversible peripheral neuropathy

FDA label

Read the full label on DailyMed ↗

BOXED WARNING Embryo-fetal toxicity: severe birth defects or embryo-fetal death even after a single dose — never use in pregnancy; REMS-restricted distribution. Venous thromboembolism: significantly increased DVT/PE risk in multiple myeloma with dexamethasone (22.5% vs 4.9%).

FDA dosing	Population	Start	Target	Max
Multiple myeloma (with dexamethasone, 28-day cycles)	Adults	200 mg QHS	200 mg QHS
Erythema nodosum leprosum, cutaneous episode	Adults (<50 kg: start low end)	100–300 mg QHS	Continue until active reaction subsides (usually ≥2 wk), then taper	400 mg/day (severe ENL; QHS or divided)

Renal Undefined

Hepatic Undefined

MM: dexamethasone 40 mg PO days 1–4, 9–12, 17–20 of each 28-day cycle

Instructions

Take with water, preferably at bedtime and ≥1 hr after the evening meal
ENL taper: 50 mg decrements q2–4wk once reaction subsides; if on maintenance, attempt taper q3–6mo
THALOMID REMS required: 2 negative pregnancy tests before start, then weekly x1 month, then monthly (q2wk if irregular cycles); 2 reliable contraception methods from 4 wk before through 4 wk after therapy; males use latex/synthetic condom and must not donate sperm; no blood donation during and 4 wk after
Interrupt for constipation, somnolence, or peripheral neuropathy; consider reduced dose on resumption
Permanently discontinue for angioedema, anaphylaxis, Grade 4 rash, skin exfoliation, or bullae

Available strengths

cap 50, 100, 150, 200 mg

Contraindications

Pregnancy — powerful human teratogen; ~40% infant mortality at or shortly after birth; discontinue immediately if pregnancy occurs

Cautions

Venous and arterial thromboembolism (DVT/PE; ischemic heart disease incl. MI; stroke) — consider thromboprophylaxis
Increased mortality when PD-1/PD-L1 blocker (pembrolizumab) added to thalidomide analogue + dexamethasone in MM
Drowsiness/somnolence — avoid hazardous tasks; additive with other sedating drugs
Peripheral neuropathy — common, may be irreversible; discontinue if symptoms occur
Dizziness and orthostatic hypotension — sit upright before standing
Neutropenia and thrombocytopenia — may need dose interruption/reduction
Increased HIV viral load — measure during treatment
Bradycardia — possible syncope; may need dose reduction/discontinuation
Severe cutaneous reactions — discontinue for severe reactions
Seizures — monitor patients with seizure history/risk factors
Tumor lysis syndrome — monitor high tumor burden

Adverse reactions

MM (≥20%): fatigue, hypocalcemia, edema, constipation, sensory neuropathy, dyspnea, muscle weakness, leukopenia/neutropenia, rash/desquamation, confusion, anorexia, nausea, anxiety/agitation, tremor, fever, weight change, thrombosis/embolism, motor neuropathy, dizziness, dry skin
ENL (≥10%): somnolence, rash, headache
DVT 13% and PE 7% (Grade 3/4) with dex in Study 2

Pregnancy Contraindicated — human teratogen; severe birth defects (amelia, phocomelia) or fetal death even after a single dose; REMS + pregnancy exposure registry

Lactation Advise women not to breastfeed during treatment

Cost

Thalidomide (THALOMID)

Strength		#/mo	CostPlus
50 mg	cap	30 qd	not offered
100 mg	cap	30 qd	not offered
150 mg	cap	30 qd	not offered
200 mg	cap	30 qd	not offered

NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Thalidomide is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

Open Thalidomide in the interactive console ↗

Self-check

What prevention program is required for thalidomide?
Pregnancy-prevention REMS.
What neurologic toxicity accumulates with thalidomide?
Peripheral neuropathy.